Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib
- 1 January 2016
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 52, 109-119
- https://doi.org/10.1016/j.ejca.2015.10.057
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical ModelsPLOS ONE, 2013
- Erratum to: Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3Angiogenesis, 2013
- Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3Angiogenesis, 2013
- Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in MelanomaPLOS ONE, 2013
- Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose MetabolismCell, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancerJournal of Molecular Signaling, 2010
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasmsBlood, 2010
- Persistent expression of PDX-1 in the pancreas causes acinar-to-ductal metaplasia through Stat3 activationGenes & Development, 2006
- Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPKNature, 2003